Kornimate/medical-research-clean huggingface dataset:
comparison of ct angiography with conventional angiography and intravascular ultrasound in heart transplant patients

Conditions: Heart Transplantation; Coronary Artery Disease

Summary: the overall goal of this study is to determine if non-invasive imaging with state of the art ct coronary angiography can be used to screen for transplant coronary artery disease in the setting of heart transplant. our current protocol at ucsf for heart transplant patients involves screening with stress tests as well as coronary angiograms with intravascular ultrasound to assess the diameter of the lumen of the coronary arteries and to assess wall thickness.

our hypothesis is that state of the art ct coronary angiography can be used to acquire data regarding the coronary arteries in the setting of heart transplant and be used to risk stratify patients with regards to the developments of transplant coronary artery disease. specific aim 1- to test the hypothesis that coronary cta can accurately measure cross-sectional vessel wall area using conventional coronary angiography with intra-vascular ultrasound as the standard of reference. specific aim 2- to test the hypothesis that coronary cta can accurately measure cross-sectional vessel wall thickness, vessel area and luminal area using conventional coronary angiography with intra-vascular ultrasound as the standard of reference. secondary aim - to asses the correlation of cross-sectional vessel wall area, vessel wall thickness, vessel area, luminal area and vessel wall index with global and regional left ventricular function using coronary cta.

Eligibility criteria:
inclusion criteria: 1. patient referred for coronary angiography and ivus as part of their standard clinical care; 2. patients must be 18 years of age or older. 3. any ethnic background is acceptable. exclusion criteria: 1. patients with contraindications for the use of iodinated contrast (allergic reaction, renal failure, multiple myeloma, etc) will be excluded. 2. patients with heart rate higher than 65 bpm and contraindications for the use of beta-blockers, listed below: systolic blood pressure \< 90mmhg decompensated congestive heart failure; copd or asthma in use of bronchodilator; second or third degree heart block; severe aortic stenosis, defined by a pressure gradient higher than 50 mmhg and/or the presence of symptoms. 3. patients with contraindications for the use of nitroglycerin, listed below: severe anemia; increased intracranial pressure; known hypersensitivity; use of sildenafil citrate (viagra®) 4. children and pregnant women will be excluded because of risks associated with radiation exposure. 5. patients must have no atrial fibrillation, as this will interfere with cardiac gating for the examination. 6. patients unable to give informed consent will be excluded as well. 7. patients with a coronary stent placed.

Keywords: transplant coronary artery disease ct angiography conventional angiography intravascular ultrasound heart transplant patients with known transplant coronary artery disease
prucalopride in pediatric subjects with functional constipation

Conditions: Functional Constipation

Summary: to evaluate the efficacy of prucalopride compared to placebo for the treatment of functional constipation in a paediatric population, aged ≥ 6 months to \< 18 years. a 16-week open-label comparator (peg) controlled part will follow, to document safety and tolerability up to 24 weeks.


Eligibility criteria:
main inclusion criteria: 1. boys and girls, aged ≥ 6 months and \< 18 years. 2. subjects with a confirmed diagnosis of functional constipation as defined by the rome iii criteria. main exclusion criteria: 1. children with underlying gi abnormalities and causes for defecation disorders. 2. constipation is thought to be drug-induced. 3. subjects suffering from secondary causes of chronic constipation.
hf tissue registry

Conditions: Heart Failure

Summary: this is a registry study. this is an observational, non-randomized, open, long-term project to collect biological samples (e.g. tissue and blood samples) in addition to clinical information and laboratory test results, from end-stage patients who undergo lvad implantation and/or heart transplantation. there are no investigational treatments, drug or procedures associated with participation in registry activities. data collection will not immediately influence the course of treatment for any patient.

after informed consent is obtained from the patient, the blood samples will be obtained either during a procedure from access lines inserted for the procedure or they will be drawn when other ordered lab work is done at specific time points. while blood samples collection is preferred, it is not required, and the decision to collect blood samples will be left to the discretion of the investigator. * tissue samples will be obtained at the time of lvad implantation by keeping the part of the left ventricular apex that the surgeon is removing in order to place the inflow cannula of the lvad. no extra tissue sample other than the tissue that has to be removed as a part of a standard lvad operation needs to be obtained. * tissue samples will be acquired from the failing heart at the time of heart transplantation, after it has been excised and a donor heart has been implanted in its place. * control tissue samples will be acquired intraoperatively during cardiac surgery wherein any amount of excised tissue is routinely discarded. in some cases, when a patient has an existing lvad implant for destination therapy, and is not eligible for cardiac transplant, and is not scheduled for cardiac surgery in the foreseeable future, the patient will be approached for consent for blood samples. in addition, consent to obtain intraoperative tissue samples is requested in the event cardiac surgery occurs and/or the device is explanted for any reason in the future.

Eligibility criteria:
inclusion criteria: 1. patients must be in one of the following groups: 1.1. patients must be eligible for a - * lvad implantation or * heart transplantation 1.2. patients must be scheduled for another type of cardiac surgery during which tissue is excised that would normally be discarded after surgery. 1.3. patients must have a vad already implanted as destination therapy with no cardiac surgery scheduled at the time of consent. 2. patients must agree to one or more blood and/or cardiac tissue sample donation(s), and longterm storage of these biological samples. 3. patients must be \> 18 years of age. exclusion criteria: patients will be excluded from the study if any of the following conditions are present: 1. the patient or the patient's personal representative is unable or unwilling to give written informed consent for participation. 2. patients who are less than 18 years of age.
eosinophilic esophagitis: towards improved management

Conditions: Eosinophilic Esophagitis

Summary: the current project aims to improve the care for children and adolescents with eosinophilic esophagitis in a collaborative effort involving pediatric units at oslo unversity hospital and helse bergen, norway. existing and new non-invasive biomarkers will be explored systematically, aiming to reduce the number of endoscopies and time on restricted diet.

the overall aim of the current proposal is to improve the care for children and adolescents with eoe and reduce the need for complex elimination diets and repeated endoscopies. our objectives are to determine whether 1. at diagnosis the following are predictive for response to food elimination: 1. history of atopy, symptoms after food intake 2. eosinophil counts in biopsies and peripheral blood 3. total ige, specific ige, eosinophilic granula proteins, eosinophil progenitor cells in blood 4. key cytokines (eotaxin-3, il-5, il-13) 5. eosinophil derived neurotoxin/edn in oesophageal aspirates, blood samples and feces 6. circulating micrornas 2. at follow-up biomarkers collected by non-invasive methods can predict endoscopic and histologic healing 1. eosinophil counts in esophageal brushes and peripheral blood 2. total ige, specific ige, eosinophilic granula protein, eosinophil progenitor cells 3. circulating cytokines like eotaxin-3, il-5, il-13 4. eosinophil derived neurotoxin/edn in esophageal brushes, blood samples and feces 5. circulating micrornas

Eligibility criteria:
inclusion criteria: * a diagnosis of eosinophilic esophagitis * suspected but not yet confirmed eosinophilic esophagitis exclusion criteria: * chronic severe conditions that preclude general anaestesia * lack of consent
demand-driven management of essential tremor

Conditions: Essential Tremor

Summary: this study evaluates the effectiveness of tremor control using various strategies for implementing demand-driven thalamic deep brain stimulation (dbs) for essential tremor. therapeutic stimulation at the vim nucleus of the thalamus will be initiated and modulated using signals derived from external sensors (e.g. emg, accelerometer) and cortical or thalamic electrodes.

essential tremor is effectively treated with deep brain stimulation of the ventralis intermedius nucleus of the thalamus, presumably because high-frequency stimulation disrupts aberrant cerebellar-thalamic input. for the most part, patients with essential tremor have a kinetic tremor that is present or worsened with movement. however, dbs therapy is currently continuous, and thus, stimulation occurs when the patient will not benefit symptomatically from treatment. this exposes the patient to unnecessary stimulation, which can lead to unnecessary usage of battery, unnecessary exposure to stimulation side-effects, and can possibly contribute to tolerance to dbs therapy. one possible solution is selective stimulation when movement is required. this study will determine signals predictive of motor activity using external sensors such as emg, and cortical biomarkers of real and imaginary movement that are well-characterized. the primary aim is to demonstrate successful initiation and modulation of dbs therapy using the activa pc+s system and implanted cortical or thalamic electrodes. putative improvements in battery usage related to stimulation on-time and definition of coupling signals between thalamus and cortex that characterize tremor state are secondary outcomes.

Eligibility criteria:
inclusion criteria: * appropriate candidates for dbs with essential tremor exclusion criteria: * not meeting inclusion criteria based on tremor amplitude, neuropsychological testing, etc. * prior trauma to the brain on side of putative implantation of stimulator

Keywords: essential tremor; closed-loop dbs
il-32 levels in patients with chronic periodontitis

Conditions: Periodontitis

Summary: interleukin-32 (il-32) is a recently described cytokine that is a strong inducer of pro-inflammatory cytokines such as tumor necrosis factor (tnf)-α. a previous report have reported that porphyromonas gingivalis-derived lps significantly up-regulated il-32 expression compared with the unstimulated cells in monocytes (thp-1 cells). they suggested that il-32 may contribute to the pathogenesis of periodontal disease. in the present study the investigators hypothesized that il-32 levels may increase in the gingival crevicular fluid (gcf) and saliva of patients with chronic periodontitis compared with healthy controls and these levels may decrease together with treatment.

the purpose of this study was to investigate il-32 levels in the gcf and saliva of patients with chronic periodontitis and to evaluate changes after nonsurgical periodontal therapy. twenty-seven cp and 27 periodontally healthy controls were enrolled in this study. periodontitis patients received nonsurgical periodontal treatment. gcf and saliva sampling and clinical periodontal parameters were assessed before and a month after treatment. il-32, il-10 and tnf-α levels in gcf and saliva were measured by enzyme-linked immunosorbent assay. unstimulated salivary samples were collected using standard techniques. about 2 ml whole saliva was collected in disposable tubes and centrifuged immediately to remove cell debris (10,000 g x 10 minutes). the supernatants (50µl each) were stored at -40c until analyzed. gcf samples were collected from a mesio-buccal and disto-palatal site on each tooth. in the cp group, the samples were obtained from patients at areas with ≥5 mm cal, ≥6 mm pd and ≥30% bone loss. in the healthy group, gcf samples were collected from teeth exhibiting pd\<3 mm without cal and bop. the area was isolated with cotton rolls, saliva contamination elimination was ensured, and it was slightly air dried. gcf was sampled with paper strips. paper strips were placed into the crevice until mild resistance was felt (intracrevicular method) and left in the position for 30 seconds. strips contaminated with blood or saliva were discarded. each sampled strip was placed into a 400µl eppendorf centrifuge tube and stored at -40c until analyzed.

Eligibility criteria:
inclusion criteria: * all subjects in the study were possess of at least 20 teeth excluding third molars. exclusion criteria: * agressive periodontitis, * periapical pathologies, * excessive forces including mechanical forces caused by orthodontic forces and occlusal forces; * presence of systemic diseases; * administration of non-steroidal and anti-inflammatory drugs or antibiotic therapies within the previous 6 months; * need for antibiotic prophylaxis for dental treatment and having received non-surgical periodontal treatment within the past 6 months or surgical periodontal treatment within the past 12 months; * allergy or sensitivity to any drug, * pregnancy, * lactation, and * current and former use of tobacco.

Keywords: interleukin-32 periodontitis
efficacy of trans abdominis plane block for post cesarean delivery analgesia

Conditions: Analgesia

Summary: relief from pain is part of the fundamental human right to health. (1) however, available evidence indicates an increasingly detailed understanding of the pathophysiology of pain and general inadequacy of its treatment.

background: relief from pain is part of the fundamental human right to health. (1) however, available evidence indicates an increasingly detailed understanding of the pathophysiology of pain and general inadequacy of its treatment. rationale: assessment and improving the pain management modality study objectives: in this study, determined the efficacy of tap block in patients undergoing cesarean section. methods: this study is a cross-sectional study. it is a multi-centric study as it was conducted in different governmental hospitals.

Eligibility criteria:
inclusion criteria: 1. age: 20-50 years 2. patients of \>50 kg or \<100 kg weight. 3. urgency: elective, emergent and urgent cases exclusion criteria: 1. patients of \ 100 kg weight 2. any contraindication to any of anesthesia medications 3. patient unable to understand numeric rating scale (nrs)

Keywords: pain cesarean delivery
effect of helicobacter pylori eradication after subtotal gastrectomy on survival rate of gastric cancer patients: retrospective study

Conditions: Gastric Cancer

Summary: in this study, we will observe the long-term survival rate, overall mortality rate, gastric cancer specific mortality rate, and the incidence rate of metachronous cancer in patients who received subtotal gastrectomy, with or without helicobacter pylori eradication.

in this study, we will observe the long-term survival rate, overall mortality rate, gastric cancer specific mortality rate, and the incidence rate of metachronous cancer in patients who received subtotal gastrectomy, with or without helicobacter pylori eradication. in addition, we will analyze the correlation between the incidence and survival rate of this type of stomach cancer by comparing smoking, gastric cancer direct family history, disease stage (tnm staging), the histologic type of stomach cancer (intestinal, diffuse, mixed), and the surgical method (billoth i, billoth ii) as well as the infection and eradication status of h. pylori.

Eligibility criteria:
inclusion criteria: * patients diagnosed with gastric cancer and received surgery (partial, distal, subtotal gastrectomy), and tested helicobacter pylori status exclusion criteria: * patients with other severe diseases (other primary cancer, severe cardiovascular, cerebral, renal, hepatic diseases) * patients received palliative treatment

Keywords: gastric cancer helicobacter pylori subtotal gastrectomy overall survival metachronous cancer
mitochondrial metabolism and hepatic complications of obesity

Conditions: Obesity

Summary: the study aims to characterize mitochondrial metabolism in the liver of obesity surgery patients and to study its relationships with hepatic steatosis, inflammation, and fibrosis.

the study aims to characterize mitochondrial metabolism in the liver of obesity surgery patients and to study its relationships with hepatic steatosis, inflammation, and fibrosis. the protocols involves a per-operative hepatic needle biopsy for mitochondria characterization and histological scoring of steatosis, inflammation, and fibrosis

Eligibility criteria:
inclusion criteria: * adult men and women * affiliated to a social security * candidate for laparoscopic obesity surgery exclusion criteria: * excessive alcohol consumption:\> 20 g / day (woman),\> 30 g / day (male) * chronic viral hepatitis b or c * genetic hemochromatosis * taking the following drugs for at least 3 months up to 6 months before the scheduled date of obesity surgery: systemic corticosteroids, amiodarone, methotrexate * wilson's disease * autoimmune hepatitis * alpha 1-antitrypsin deficiency * abetalipoproteinemia * contraindications to liver biopsy

Keywords: obesity surgery liver mitochondria steatosis
simulation of risk of adverse drug events associated with the initiation of drugs repurposed for the treatment of covid-19 in adults with polypharmacy using data from large medicare and commercially insured populations

Conditions: COVID; Drug Effect; Drug Interaction; Adverse Drug Event

Summary: this retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the medication risk score (mrs) in a health insurance population. our clinical tool would enable us to identify potential multi-drug interactions and potentially reduce the risk of adverse drug events (ade) developing in these patients infected with covid-19.

certain investigational agents have been described in observational series or are being used anecdotally based on in vitro or extrapolated evidence. it is important to acknowledge that there are no controlled data supporting the use of any of these agents, and their efficacy for covid-19 is unknown. fda-approved drugs such as chloroquine/hydroxychloroquine, lopinavir/ritonavir, monoclonal il-6 antibodies, jak inhibitors, thalidomide, and the new investigational drug remdesivir, have been proposed for repurposing to fight covid-19 and its complications. a medication risk stratification strategy will be used to simulate the impacts of different potential repurposed drugs for covid-19 and the medication risk score (mrs) which is used as a predictive tool for ades. a retrospective study will be conducted using de-identified drug claims data for commercially insured patients.

Eligibility criteria:
inclusion criteria: * patients enrolled with cambia health solutions; medicare/medicaid or commercial health insurance plan * patients with drug claims available from 10/01/2018 to 10/31/2019 exclusion criteria: * patients with no drug claims available for 2018 * health plan for injectable drugs

Keywords: covid-19 repurposed drug drug interaction lqts
the effect of tranexamic acid on blood loss and transfusion requirements following open femur fracture surgery

Conditions: Blood Loss Following Open Femur Fracture Surgery

Summary: the purpose of this study is to determine the effect of tranexamic acid (txa) on blood loss and transfusion requirements in patients with femur fractures requiring open surgical approaches.


Eligibility criteria:
inclusion criteria: * patients admitted to memorial hermann medical center with acute femur fractures that require open surgical approaches for fracture reduction and implant application, including patients with subtrochanteric, high-energy intertrochanteric, periprosthetic, and intra-articular distal femur fractures. exclusion criteria: * preoperative use of any anticoagulant * history of deep venous thrombosis or pulmonary embolus * allergy to txa * hepatic dysfunction (ast/alt \> 60) * renal dysfunction (cr \> 1.5 or gfr \< 30) * history of cerebrovascular accident in the past 12 months * active coronary artery disease (event in the past 12 months) * presence of drug-eluting stent * color blindness * presence of an additional acute injury that could contribute to blood transfusion requirements
one year drug treatment in first-episode schizophrenia

Conditions: Schizophrenia

Summary: prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.

the objective of this multi-center study is to optimize the long-term treatment of patients with first episode schizophrenia. this investigation should contribute to the issue of effective relapse prevention in first-episode patients. 1-year maintenance neuroleptic treatment is done with low dose haloperidol or risperidone (target dose 2-4 mg/die).

Eligibility criteria:
inclusion criteria: * after the acute treatment of the first-episode in schizophrenia (according icd-10 f20) * age between 18 and 55 * informed consent exclusion criteria: * residence outside of the catchment area * legal reasons * insufficient knowledge of the german language * substance abuse or addiction * pregnancy * serious physical illness * organic brain disease * contraindication to neuroleptic treatment

Keywords: schizophrenia first episode long-term treatment typical vs. atypical neuroleptics